Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 11/20 | 0.49 |
| ▸ | HCRTR2 | O43614 | 11/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | PTGES | O14684 | 2/20 | 0.42 |
| ▸ | PRCP | P42785 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1982288 | 1.00 | HCRTR1 (0.49) | HCRTR1HCRTR2KMT2AUSP30PTGES | |
| SCHEMBL1982286 | 1.00 | HCRTR1 (0.49) | HCRTR1HCRTR2KMT2AUSP30PTGES | |
| SCHEMBL12567373 | 0.97 | HCRTR1 (0.47) | HCRTR1HCRTR2KMT2AUSP30PTGES | |
| SCHEMBL2706134 | 0.92 | HCRTR1 (0.58) | HCRTR1HCRTR2 | |
| SCHEMBL1293520 | 0.92 | HCRTR1 (0.58) | HCRTR1HCRTR2 | |
| SCHEMBL38658108 | 0.92 | HCRTR1 (0.58) | HCRTR1HCRTR2 | |
| SCHEMBL204028 | 0.92 | HCRTR1 (0.58) | HCRTR1HCRTR2 | |
| SCHEMBL1293966 | 0.92 | HCRTR1 (0.48) | HCRTR1HCRTR2USP30PRCP | |
| SCHEMBL12798828 | 0.91 | HCRTR1 (0.49) | HCRTR1HCRTR2KMT2A | |
| SCHEMBL12509692 | 0.89 | HCRTR1 (0.46) | HCRTR1HCRTR2PTGESPRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590062-B2 | PD-1/PD-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| EP-4026835-A2 | PD-1/PD-L1 INHIBITORS | Gilead Sciences, Inc. (US) | 2022-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12590062-B2 | PD-1/PD-L1 inhibitors | CD274, PDCD1LG2, PDCD1 | HCRTR1 110/4885HCRTR2 136/4885KMT2A 1216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.